SEARCH

SEARCH BY CITATION

References

  • 1
    Radtke MA , Schäfer I , Gajur A , Langenbruch A , Augustin M . Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009;161:134139.
  • 2
    Taïeb A , Picardo M . Clinical practice. Vitiligo N Engl J Med 2009;360:160169.
  • 3
    The Vitiligo Japanese Task Force. The Establishment of Guideline for the Diagnosis and Treatment of Vitiligo in Japan. Research for Incurable Disorders. Ministry of Health, Labour and Welfare in Japan. 2010. (in Japanese)
  • 4
    Suzuki T , Kaneda M , Tanemura A et al. Guideline for the diagnosis and treatment of vitiligo in Japan. Guideline for the management of vitiligo. Jpn J Dermatol 2012; 122: 17251740. (in Japanese)
  • 5
    Saida T , Manabe M , Takenouchi T et al. Guidelines for management of skin cancer. Jpn J Dermatol 2007; 117: 18551925. (in Japanese)
  • 6
    Furue M , Yamazaki S , Jimbou K et al. A national seasonal survey of patients with dermatologic disorders in clinics and hostitals in Japan. Jpn J Dermatol 2009; 119: 17951809. (in Japanese)
  • 7
    Lerner AB . On the etiology of vitiligo and gray hair. Am J Med 1971;51:141147.
  • 8
    Howitz J , Brodthagen H , Schwartz M , Thomsen K . Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:4752.
  • 9
    Venneker GT , de Waal LP , Westerhof W , D'Amaro J , Schreuder GM , Asghar SS . HLA associations in vitiligo patients in the Dutch population. Dis Markers 1993;11:187190.
  • 10
    Majumder PP , Nordlund JJ , Nath SK . Pattern of familial aggregation of vitiligo. Arch Dermatol 1993;129:994998.
  • 11
    Ando I , Chi HI , Nakagawa H , Otsuka F . Difference in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type. Brit J Dermatol 1993;129:408410.
  • 12
    Jin Y , Mailloux CM , Gowan K et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:12161225.
  • 13
    Cui J , Harning R , Henn M , Bystryn JC . Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162165.
  • 14
    Norris DA , Horikawa T , Morelli JG . Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994;7:193203.
  • 15
    Lang KS , Caroli CC , Muhm A et al. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. Pigment Cell Res 1994;7:193203.
  • 16
    Schallreuter KU , Wood JM , Ziegler I et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1994;1226:181192.
  • 17
    Passi S , Grandinetti M , Maggio F , Stancato A , De Luca C . Epidermal oxidative stress in vitiligo. Pigment Cell Res 1998;11:8185.
  • 18
    Al'Abadie MS , Senior HJ , Bleehen SS , Gawkrodger DJ . Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131: 160165.
  • 19
    Lazarova R , Hristakieva E , Lazarov N , Shani J . Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol Biochem 2000;108:262267.
  • 20
    Sugita S , Takase H , Taguchi C et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 2006;47:25472554.
  • 21
    Charles CR , Sire DJ , Johnson BL , Beidler JG . Hypopigmentation in tinea versicolor: a histochemical and electronmicroscopic study. Int J Dermatol 1973;12:4858.
  • 22
    Nazzaro-Porro M , Passi S . Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978;71:205208.
  • 23
    Sanchez MR . Syphilis. In: Freedberg IM , Eisen AZ , Wolff K , Austen KP , Goldsmith LA , Katz Fitzpatrick TB , eds. Dermatology in General Medicine, 5th edn. New York: McGraw-Hill, 1999; 25512581.
  • 24
    Saeki H , Furue M , Furukawa F et al. Guidelines for managements of atopic dermatitis. J Dermatol 2009;36:563577.
  • 25
    Hamzavi I , Jain H , McLean D et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004; 140: 677683. (evidence level III)
  • 26
    Njoo MD , Spuls PI , Bos JD , Westerhof W , Bossuyt PM . Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998; 134: 15321540. (evidence level I)
  • 27
    Clayton R . A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977; 96: 7173. (evidence level II)
  • 28
    Arca E , Taştan HB , Erbil AH , Sezer E , Koç E , Kurumlu Z . Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006; 33: 338343 (evidence level III).
  • 29
    Kumaran MS , Kaur I , Kumar B . Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 269273. (evidence level III)
  • 30
    Ermis O , Alpsoy E , Cetin L , Yilmaz E . Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001; 145: 472475. (evidence level II)
  • 31
    Radakovic S , Breier-Maly J , Konschitzky R et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol 2009; 23: 951953. (evidence level II)
  • 32
    Hartmann A , Bröcker EB , Hamm H et al. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Derm Venereol 2008; 88: 474479. (evidence level III)
  • 33
    Drake LA , Dinehart SM , Farmer ER et al. Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol 1996; 35: 620626. (evidence level VI)
  • 34
    Kwok YK , Anstey AV , Hawk JL . Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol, 2002; 27: 104110. (evidence level III)
  • 35
    Westerhof W , Nieuweboer-Krobotova L . Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133: 15251528. (evidence level III)
  • 36
    Njoo MD , Bos JD , Westerhof W . Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245253. (evidence level III)
  • 37
    Scherschun L , Kim JJ , Lim HW . Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44: 9991003. (evidence level IV)
  • 38
    Yones SS , Palmer RA , Garibaldinos TM , Hawk JL . Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 2007; 143: 578584. (evidence level I)
  • 39
    Gawkrodger DJ , Ormerod AD , Shaw L et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 10511076. (evidence level IV)
  • 40
    Kunisada M , Kumimoto H , Ishizaki K et al. Narrow-band UVB induces more carcinogenic skin tumors than broad-band UVB through the formation of cyclobutane pyrimidine dimer. J Invest Dermatol 2007; 127: 28652871. (evidence level IV)
  • 41
    Young AR . Carcinogenecity of UVB phototherapy associated. Lancet 1995; 345: 14311432. (evidence level V)
  • 42
    Nicolaidou E , Antoniou C , Stratigos A , Katsambas AD . Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. J Am Acad Dermatol 2009; 60: 470477. (evidence level III)
  • 43
    Shen Z , Gao T-W , Chen L et al. Optimal frequency of treatment with the 308-nm excimer laser for vitiligo on the face and neck. Photomed Laser Surg 2007; 25: 418427. (evidence level III)
  • 44
    Casacci M , Thomas P , Pacifico A , Bonnevalle A , Paro VidolinA , Leone G . Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo – a multicentre controlled study. J Eur Acad Dermatol Venereol 2007; 21: 956963. (evidence level III)
  • 45
    Kim SM , Lee HS , Hann SK . The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38: 546550. (evidence level IV)
  • 46
    Seiter S , Ugurel S , Tilgen W , Reinhold U . Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000; 39: 624627. (evidence level IV)
  • 47
    Njoo MD , Westerhof W , Bos JD , Bossuyt PM . A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998; 134: 15431549. (evidence level I)
  • 48
    Falabella R , Barona MI . Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res 2009; 22: 4265. (evidence level II or more)
  • 49
    Hanafusa T , Yamaguchi Y , Nakamura M et al. Establishment of suction blister roof grafting by injection of local anesthesia beneath the epidermis: less painful and more rapid formation of blisters. J Dermatol Sci 2008; 50: 243247. (evidence level V)
  • 50
    Ongenae K , Dierckxsens L , Brochez L , van GeelN , Naeyaert JM . Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005; 210: 279285. (evidence level IV)
  • 51
    Tanioka M , Yamamoto Y , Kato M , Miyachi Y . Camouflage for patients with vitiligo vulgaris improved their quality of life. J Cosmet Dermatol 2010; 9: 7275. (evidence level IV)